Medical Device News Magazine

Medtronic Introduces a New Program Called My InsightsZ: Exclusively Made for Individuals Using the MiniMed™ 770G System

About Medical Device News Magazine

About Medical Device News Magazine. We are a digital publication founded in 2008 located in the United States.

Advertise with Medical Device News Magazine! Join Our #1 Family of Advertisers!

We pride ourselves on being the best-kept secret when it comes to distributing your news! Our unique digital approach enables us to circulate your...

Using an individual’s data, My Insights relies on the power of data science to provide personalized tips, trends, and reminders that customers can use to help with their diabetes management goals. The My Insights personalized recommendations are shared via a monthly email with educational content that is most relevant based on what an individual may currently be experiencing.

This is the first program in diabetes management that goes beyond generalized tips and instead shares personalized suggestions using data from an integrated pump system.

The launch of this program adds to a list of first-of-its-kind innovations and programs that Medtronic has brought to its patients to augment their diabetes management. This includes the first system to integrate insulin pumps and continuous glucose monitors (CGM), the first technology to suspend insulin delivery and reduce severe lows, the first Smart Insulin Pen, the first system to automatically adjust background insulin, the first stand-alone CGM with predictive alerts, and the first extended infusion set for up to seven days of wear.

“With diabetes, I have a lot to keep track of to stay healthy. My Insights provides me with personalized tips on how to improve the experience of my MiniMed 770G pump system,” said Melanie Licnerski who has been using Medtronic technology for over two decades. “I did not expect the emotion I got from the encouragement that My Insights provides. I didn’t realize that was something I was missing and really appreciated.”

By proactively identifying challenges and helping to celebrate successes, My Insights adds to the experience MiniMed 770G system provides to customers. The MiniMed 770G pump system, which is available to people living with diabetes who are ages two and above, uses self-adjusting technology to help prevent highs and lows in blood glucose levels by automatically adjusting insulin delivery every 5 minutes to adapt to an individual’s unique needs.* It also uses smart phone connectivity to view, share, and automatically upload insulin and CGM data, and provides access to future innovations via software upgrades.

“Our goal is to make life easier for individuals living with diabetes,” said Que Dallara, executive vice president & president, Medtronic Diabetes. “As we continue our journey towards a fully automated insulin delivery system, we want to surround our customers with holistic support and empower them with tools to help them achieve their goals. Diabetes is deeply personal and unique for every individual, and we’re pleased to offer this level of personalization.”

My Insights is available in the U.S. to those who use the MiniMed 770G system. Users can opt-in to receive My Insights emails at Diabetes.shop.

*Refers to SmartGuard™ Auto Mode. Some user interaction required. Individual results may vary.

Medical Device News Magazinehttps://infomeddnews.com
Medical Device News Magazine provides breaking medical device / biotechnology news. Our subscribers include medical specialists, device industry executives, investors, and other allied health professionals, as well as patients who are interested in researching various medical devices. We hope you find value in our easy-to-read publication and its overall objectives! Medical Device News Magazine is a division of PTM Healthcare Marketing, Inc. Pauline T. Mayer is the managing editor.

Other News

Shoulder Innovations Further Strengthens IP Portfolio in Key Areas with Recent Patent Grants

"These recent grants further strengthen key patent families that are foundational to our technology, and we are pleased the USPTO continues to recognize our meaningful innovation in the shoulder arthroplasty segment," said Rob Ball, CEO of Shoulder Innovations. "This noteworthy expansion of our IP position represents the culmination of over 10 years of research and development, and we are proud of our team for their continued dedication to creating practical solutions for shoulder surgeons and advancing patient outcomes."

Radical Catheter Technologies Presents Analysis of Disruptive, Recently FDA-Cleared Endovascular Technology at the Society of NeuroInterventional Surgery 21st Annual Meeting

This new catheter, the first product commercialized from this novel technology platform, is designed to enable access to the blood vessels in the brain for both femoral and radial access. A multi-center analysis of this disruptive technology is being presented today at Society of NeuroInterventional Surgery 21st annual meeting. In addition, the Company confirmed the closing of a $20 million financing round led by NeuroTechnology Investors, which will be used to scale the company and expand the Radical platform notes Radical Catheter Technologies.

Rapid Medical™ Completes Initial Neurovascular Cases in the USA Following FDA Clearance of Its Active Access Solution

“With DRIVEWIRE, our design goal was to bring new levels of access and control to the interventional suite while improving best-in-class guidewires,” comments Giora Kornblau, Chief Technology Officer at Rapid Medical. “When physicians are looking for technologies that increase the clinical possibilities and safety for the patient, we want Rapid to be the first place they look.”